Author’s response to reviews

Title: Blocking podoplanin suppresses growth and pulmonary metastasis of human malignant melanoma

Authors:
Mengqiao Xu (xumengqiaobox@163.com)
Xia Wang (tutu0416@163.com)
Yanfang Pan (yanfang.pan@drug-farm.com)
Xingpeng Zhao (zhaoaxing2013@163.com)
Bin Yan (sudayanbin@163.com)
Changgeng Ruan (ruanchanggeng@suda.edu.cn)
Lijun Xia (lijun-xia@omrf.org)
Yiming Zhao (zhaoyimingbox@163.com)

Version: 4  Date: 04 Jun 2019

Author’s response to reviews:

Dr. Linda Gummlich
Editor-in-Chief
BMC Cancer
RE: Manuscript BCAN-D-19-00027R3

Dear Dr. Gummlich,

We are happy to know that our manuscript has been accepted pending some minor revisions. We have made these additional changes suggested by you and reviewers. A clean version of our revised manuscript has been submitted. Below are our point-by-point responses.

1 - Please clarify in the Ethics approval and consent to participate section whether the blood donors provided written informed consent to participate in this study. If the consent was verbal or there was a waiver, please give a reason for this and whether the Ethics Board approved it.

A.Done as suggested.(Methods section,underPlatelet aggregation assay, line 21-22, page 5).
2 - In the Funding section of the Declarations please indicate the role of the funding body in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript. If no specific funding was received for this study, please clearly indicate this in the Funding section.

A. Done as suggested. (Declarations section, under Funding, line 16-18, page 13).

In addition, the English in the manuscript has been edited by an expert who is fluent in English.

We hope our manuscript is now acceptable for publication.

Sincerely,

Yiming Zhao, PhD.

Email: zhaoyimingbox@163.com